# Abemaciclib

## Verzenio 150mg (28 tablets/box)

##### 臨採

| TAH Drug Code      | [OVERZ](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OVERZ)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast cancer, Advanced or metastatic, hormone receptor-positive disease, HER2-negative, in combination with an aromatase inhibitor for initial endocrine therapy in postmenopausal women and men. Breast cancer, Advanced or metastatic, hormone receptor-positive disease, HER2-negative, in combination with fulvestrant for progression following endocrine therapy. Breast cancer, Advanced or metastatic, hormone receptor-positive disease, HER2-negative, monotherapy for progression following endocrine therapy and prior chemotherapy in the metastatic setting. Breast cancer, Early, hormone receptor-positive, HER2-negative, node-positive, high-risk, in combination with adjuvant endocrine therapy.                                                                                                                                         |
| Dosing             | In combination with fulvestrant, tamoxifen, or an aromatase inhibitor, the recommended dose is 150 mg taken orally twice daily. As monotherapy, the recommended dose is 200 mg taken orally twice daily. Dose Modifications for Adverse Reactions: In combination with fulvestrant, tamoxifen, or an aromatase inhibitor: Recommended starting dose: 150 mg twice daily -> First dose reduction: 100 mg twice daily -> Second dose reduction: 50 mg twice daily -> Third dose reduction: not applicable. As monotherapy: Recommended starting dose: 200 mg twice daily -> First dose reduction: 150 mg twice daily -> Second dose reduction: 100 mg twice daily -> Third dose reduction: 50 mg twice daily.                                                                                                                                                   |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Contraindications  | Allergic to the active ingredients or excipients in Verzenio.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Adverse Effects    | Common Gastrointestinal: Abdominal pain (29% to 39% ), Decrease in appetite (12% to 45% ), Diarrhea, All Grades (81% to 90% ), Nausea (39% to 64% ), Vomiting (26% to 35% ) Hematologic: Anemia, All Grades (25% to 29% ), Leukopenia, All Grades (17% to 28% ), Neutropenia, All Grades (37% to 46% ) Immunologic: Infectious disease (31% to 51% ) Neurologic: Headache (20% ) Other: Fatigue (40% to 65% ) Serious Gastrointestinal: Diarrhea, Grade 3 (8% to 20% ) Hematologic: Febrile neutropenia (Less than 1% ), Neutropenia, Grade 3 or higher (19% to 32% ), Neutropenic sepsis, Venous thromboembolism (2% to 5% ) Hepatic: ALT/SGPT level raised (Grade 3 or higher, 2% to 6% ), Aspartate aminotransferase serum level raised (Grade 3 or higher, 2% to 3% ) Neurologic: Cerebral infarction Respiratory: Interstitial lung disease, Pneumonitis |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

